Zacks.com on MSN3d
GILD Stock Down on Report of Cut in HIV Prevention Spending
Gilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...
News241d
A jab that could protect against HIV for a year at a time
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell?
Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the ...
Wall Street weighs in on Gilead as shares fall on possible U.S. HIV cuts
Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health and Human Services Department is considering major cuts to federal funding for domestic HIV ...
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval
Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...
HIV Drug Makers Get Spooked by Possible Trump Cut, but Impact Looks Manageable
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
Yearly HIV prevention injection shows promise in clinical trial
Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.
Investing4d
Gilead Sciences’ SWOT analysis: HIV giant’s stock faces pivotal transition
Gilead Sciences stands at a crossroads, balancing its established HIV franchise with emerging opportunities in oncology and other therapeutic areas. The success of lenacapavir in PrEP and the ...
Oppenheimer doesn’t see threat to Gilead estimates after HHS plans for HIV cuts
Oppenheimer notes that Gilead (GILD) shares are weak today following reports from multiple media outlets that the Health and Human Services ...
JPMorgan sees CDC funding report not impacting Gilead story
JPMorgan says that while the Wall Street Journal’s report on potential Centers for Disease Control and Prevention funding cuts for HIV ...
allAfrica.com on MSN2d
Africa: A Jab That Could Protect Against HIV for a Year At a Time, and Other Highlights From Major Conference
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...